The present disclosure provides a healthcare management method comprising acquiring a first data that includes a glycoalbumin concentration and an albumin concentration in a body fluid from a subject; generating, on the basis of the first data, output information related to the GA value; and providing the generated output information to a user.

Described herein is a method for mixing unequal amounts of two reagents to produce a detectable reaction in a microfluidic chip. In one example, there is a fluorescent microfluidic urinary albumin chip (UAL-Chip) that exploits the nonimmunological fluorescent assay. In this chip, we constructed a passive and continuous mixing module, in which the loading process requires only an inexpensive dropper, and the signal is stable over time, as discussed below. We applied a pressure-balancing strategy based on the immiscible oil coverage which highly improves the precision in controlling the mixing ratio of sample and dye. The UAL-Chip has achieved an estimated limit of detection (LOD) of 8.4 μg/ml using albumin standards, which is below the 30 μg albumin per ml urine level considered to be indicative of kidney damage.

This present disclosure provides methods and compositions that can be used to quantify cfDNA in biofluids using a hybridization approach.

The present disclosure relates to using spectrophotometry to estimate genome copies and full/empty ratios adeno-associated virus particles.

The present invention relates to microsomes bound to magnetizable beads and their use in studying or determining drug metabolism. Compositions, methods, kits and systems involving the magnetizable bead-bound microsomes are described herein.

A urine sample testing apparatus may include a urine qualitative measuring section configured to acquire a measurement result for each of a plurality of urine qualitative measurement items and a urine sediment measuring section configured to acquire a measurement result for each of a plurality of urine sediment measurement items. The apparatus may also include an operation part that can specify a combination of one of the plurality of urine qualitative measurement items and one of the plurality of urine sediment measurement items. An information processing unit may also be included.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Biochemical test methods for protein quantification can include application of foam-suppressing and/or foam-destroying substances to avoid readout problems and ensure the accuracy of measurement results. One such method for determining the amount of one or more proteins in a solution includes providing at least a first solution that is known to contain or suspected of containing one or more protein(s), adding at least one foam-suppressing and/or foam-destroying substance to the first solution, resulting in a second solution, and determining the amount of the one or more protein(s) in the second solution.

A multiplex proteome quantification method based on isobaric dimethyl labeling implements dimethyl labeling of peptide N-terminal in an acidic condition and C-terminal in an alkaline condition one after another by means of Hall the property that a dimethylation reaction has different rates on an amino group at the peptide N-terminal and an amino group on a Lysine side chain at the peptide C-terminal in the acidic condition. Multiplex labeling of peptide samples is implemented by means of the organic combination of various isotope forms of a dimethyl labeling reagents. The mass-to-charge ratios in MS1 of peptides after multiplex labeling are completely the same, the mass-to-charge ratios of the fragment ions in MS2 are different, and multiplex quantitative analyses are carried out by extracting the intensity values of corresponding fragment ions in the MS2.

A method for diagnosis of IgA nephropathy is provided using a combination of alpha-1B-glycoprotein (A1BG) or a truncated fragment thereof having a molecular weight of 13-60 kDa, orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from a subject.